Xencor, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $34.50
- 52-Week Range
- $10.38 – $40.60
- Market Cap
- $2.58B
- P/E (TTM)
- —
- EPS (TTM)
- -1.55
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 4.59
- PEG Ratio
- —
- Return on Equity
- -19.88%
- Return on Assets
- -11.11%
- Gross Margin
- -42.50%
- Operating Margin
- -72.67%
- Profit Margin
- -58.79%
- Current Ratio
- 6.54
- Debt/Equity
- 0.29
- Total Debt
- $160.23M
- Free Cash Flow
- $-96.22M
- Revenue Growth
- 454.90%
- Earnings Growth
- —
- Enterprise Value
- $2.34B
Market Snapshot
About
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. The company uses its proprietary XmAb protein engineering technology platform to create next-generation antibody therapeutics with improved efficacy and safety profiles. Xencor has multiple product candidates in clinical development and partners with leading pharmaceutical companies.